Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab.
Mathilde BureauThierry ChatellierTanguy PerennecThomas GoronflotCharlotte GreilsamerAnne-Laure CheneRaafet AffiEric FrampasJaafar BennounaElvire Pons-TostivintPublished in: Cancer immunology, immunotherapy : CII (2021)
After adjustment on major baseline clinical prognostic factors, BTS was an independent prognostic factor for OS in PD-L1 ≥ 50% advanced NSCLC patients treated first-line with pembrolizumab.